Cardiovascular risk in patients with selected cutaneous diseases
DOI:
https://doi.org/10.12775/JEHS.2022.12.07.011Keywords
dermatology, cardiology, psoriasis, scleroderma, lupus erythematosusAbstract
Introduction and purpose: Cardiovascular diseases (CVD) are the leading cause of death worldwide. The classic cardiovascular risk factors include age, gender, obesity, diabetes, hypertension, dyslipidemia, smoking and genetic factors. Some dermatological disorders are also potential risk factors for the development of CVD. The aim of the study is to review recent knowledge on the impact of dermatological diseases on cardiovascular risk.
Description of the state of knowledge: The relationship between skin diseases and cardiovascular risk is influenced by various common dependencies such as: shared pathophysiological basis of disorders, risk factors, presence of a chronic inflammatory process, genetic susceptibility and environmental influences. Increased cardiovascular risk has been reported for several dermatological conditions, including psoriasis, systemic lupus erythematosus, systemic sclerosis, pemphigus, hidradenitis suppurativa, rosacea, atopic dermatitis. Chronic systemic inflammation, typically present in skin conditions, is a cardiovascular risk factor, because inflammation accelerates atherosclerosis, and furthermore may predispose patients to the development of metabolic syndrome, insulin resistance and diabetes mellitus. In patients who are initially metabolically unbalanced, these processes may be even more intense. Cardiovascular disorders, the frequency of which increases in patients with skin diseases, include atherosclerosis, coronary artery disease, ischemic heart disease, cardiac dysfunction, arrhythmias, heart failure, cerebrovascular disease (stroke, TIA) and peripheral arterial disease.
Summary: Many cutaneous disorders, in addition to significantly increasing cardiovascular morbidity and mortality, also reduce the patient's quality of life. The cooperation of dermatologists and cardiologists in the care of patients with dermatological diseases is crucial for the proper treatment of the disease and prevention of cardiovascular complications.
References
Francula-Zaninovic S, Nola IA. Management of Measurable Variable Cardiovascular Disease' Risk Factors. Curr Cardiol Rev. 2018;14(3):153-163. doi:10.2174/1573403X14666180222102312.
Caforio ALP, Adler Y, Agostini C, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017;38(35):2649-2662. doi:10.1093/eurheartj/ehx321.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. doi:10.1016/S0140-6736(14)61909-7.
Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2017;19(1):58. Published 2017 Dec 25. doi:10.3390/ijms19010058.
von Stebut E, Boehncke WH, Ghoreschi K, et al. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Front Immunol. 2020;10:3096. Published 2020 Jan 15. doi:10.3389/fimmu.2019.03096.
Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(13):1670-1680. doi:10.1016/j.jacc.2021.02.009.
Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700-703. doi:10.1001/archdermatol.2009.94.
Ahlehoff O, Skov L, Gislason G, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One. 2012;7(4):e36342. doi:10.1371/journal.pone.0036342.
Mahiques-Santos L, Soriano-Navarro CJ, Perez-Pastor G, Tomas-Cabedo G, Pitarch-Bort G, Valcuende-Cavero F. Psoriasis and ischemic coronary artery disease. Actas Dermosifiliogr. 2015;106(2):112-116. doi:10.1016/j.ad.2014.08.002.
Shiba M, Kato T, Funasako M, et al. Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan [published correction appears in PLoS One. 2016;11(6):e0158699]. PLoS One. 2016;11(2):e0149316. Published 2016 Feb 24. doi:10.1371/journal.pone.0149316.
Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. J Autoimmun. 2017;(82):1-12. doi:10.1016/j.jaut.2017.05.008.
Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331-2337. doi:10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i
Piranavan P, Perl A. Management of cardiovascular disease in patients with systemic lupus erythematosus. Expert Opin Pharmacother. 2020;21(13):1617-1628. doi:10.1080/14656566.2020.1770227
Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(5):441-448. doi:10.1097/BOR.0000000000000528.
Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408-415. doi:10.1093/oxfordjournals.aje.a009122.
Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev [Internet]. 2013 2 1;9(1):15–9.
Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual. Lupus. 2007;16(5):309-317. doi:10.1177/0961203307077987.
Tektonidou MG, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. Autoimmun Rev. 2017;16(3):308-312. doi:10.1016/j.autrev.2017.01.009.
Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study [published correction appears in J Rheumatol. 2010 Oct;37(10):2198]. J Rheumatol. 2010;37(2):322-329. doi:10.3899/jrheum.090306.
Tumurkhuu G, Montano E, Jefferies C. Innate Immune Dysregulation in the Development of Cardiovascular Disease in Lupus. Curr Rheumatol Rep. 2019;21(9):46. Published 2019 Jul 23. doi:10.1007/s11926-019-0842-9.
Ferri C, Giuggioli D, Sebastiani M, Colaci M, Emdin M. Heart involvement and systemic sclerosis. Lupus. 2005;14(9):702-707. doi:10.1191/0961203305lu2204oa.
Aguglia G, Sgreccia A, Bernardo ML et al. Left ventricular diastolic function in systemic sclerosis. J Rheumatol 2001; 28: 1563–1567.
Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am. 1996;22(4):841-860. doi:10.1016/s0889-857x(05)70304-5.
Roberts NK, Cabeen WR Jr, Moss J, Clements PJ, Furst DE. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med. 1981;94(1):38-40. doi:10.7326/0003-4819-94-1-38.
Ferri C, Emdin M, Giuggioli D, et al. Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheumatol. 1997;36(6):669-676. doi:10.1093/rheumatology/36.6.669
Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol. 1998;37(7):750-755. doi:10.1093/rheumatology/37.7.750.
Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139-153. doi:10.1097/00005792-200203000-00004.
Frustaci A, Francone M, Verardo R, et al. Pemphigus-associated cardiomyopathy: report of autoimmune myocarditis and review of literature. ESC Heart Fail. 2021;8(5):3690-3695. doi:10.1002/ehf2.13474.
Abreu Velez AM, Howard MS, Velazquez-Velez JE. Cardiac rhythm and pacemaking abnormalities in patients affected by endemic pemphigus in Colombia may be the result of deposition of autoantibodies, complement, fibrinogen, and other molecules. Heart Rhythm. 2018;15(5):725-731. doi:10.1016/j.hrthm.2017.12.023.
Shahidi-Dadras M, Pishgahi M, Tabary M, et al. Cardiac function in pemphigus vulgaris patients before and after steroid pulse therapy. J Dermatolog Treat. 2021;32(7):855-859. doi:10.1080/09546634.2019.1708850.
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058. doi:10.1016/j.jaad.2019.08.090.
Pescitelli L, Ricceri F, Prignano F. Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol. 2018 Jun;153(3 Suppl 2):8-17.
Juhl CR, Miller IM, Jemec GB, Kanters JK, Ellervik C. Hidradenitis suppurativa and electrocardiographic changes: a cross-sectional population study. Br J Dermatol. 2018;178(1):222-228. doi:10.1111/bjd.15778.
Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2016;152(4):429-434. doi:10.1001/jamadermatol.2015.6264.
Miller IM, Ahlehoff O, Zarchi K, et al. Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities. Br J Dermatol. 2018;178(3):790-791. doi:10.1111/bjd.15998.
Alatas ET, Biteker M, Alatas OD. Epicardial fat thickness is ıncreased and associated with disease severity in hidradenitis suppurativa. Arch Dermatol Res. 2020;312(7):467-472. doi:10.1007/s00403-019-02032-6.
Ahn CS, Huang WW. Rosacea Pathogenesis. Dermatol Clin. 2018;36(2):81–86. doi:10.1016/j.det.2017.11.001.
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749-760. doi:10.1016/j.jaad.2014.08.028.
Duman N, Ersoy Evans S, Atakan N. Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol. 2014;28(9):1165-1169. doi:10.1111/jdv.12234.
Dosal JR, Rodriguez GL, Pezon CF, Li H, Keri JE. Effect of tetracyclines on the development of vascular disease in veterans with acne or rosacea: a retrospective cohort study. J Invest Dermatol. 2014;134(8):2267-2269. doi:10.1038/jid.2014.148.
Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: The cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15(1):40-47. doi:10.1038/jidsymp.2011.9.
Hayran Y, Lay I, Mocan MC, Bozduman T, Ersoy-Evans S. Vascular endothelial growth factor gene polymorphisms in patients with rosacea: A case-control study. J Am Acad Dermatol. 2019;81(2):348-354. doi:10.1016/j.jaad.2019.03.055.
Bot I, van Berkel TJ, Biessen EA. Viral serine protease inhibitors as anti-atherosclerotic therapy. Curr Opin Investig Drugs. 2007;8(9):729-735.
Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019 Mar; 40(2): 84–92.
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Fuxench ZCC. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018 Nov;121(5):604-612.e3.
Schmidt SAJ, Olsen M, Schmidt M, et al. Atopic dermatitis and risk of atrial fibrillation or flutter: A 35-year follow-up study. J Am Acad Dermatol. 2020;83(6):1616-1624. doi:10.1016/j.jaad.2019.08.039.
Kwa MC, Silverberg JI. Association Between Inflammatory Skin Disease and Cardiovascular and Cerebrovascular Co-Morbidities in US Adults: Analysis of Nationwide Inpatient Sample Data. Am J Clin Dermatol. 2017;18(6):813-823. doi:10.1007/s40257-017-0293-x.
Ascott A, Mulick A, Yu AM, Prieto-Merino D, Schmidt M, Abuabara K, Smeeth L, Roberts A, Langan SM. Atopic eczema and major cardiovascular outcomes: A systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol. 2019 May;143(5):1821-1829.
Bulger DA, Minhas S, Asbeutah AA, et al. Chronic Systemic Inflammatory Skin Disease as a Risk Factor for Cardiovascular Disease. Curr Probl Cardiol. 2021;46(5):100799. doi:10.1016/j.cpcardiol.2021.100799.
Katsambas A, Stefanaki C. Life-threatening dermatoses due to connective tissue disorders. Clin Dermatol. 2005 May-Jun;23(3):238-48. doi: 10.1016/j.clindermatol.2004.06.004. PMID: 15896538.
Gisterå A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol. 2017;13(6):368-380. doi:10.1038/nrneph.2017.51.
Wong ND, Budoff MJ, Ferdinand K, et al. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. Am J Prev Cardiol. 2022;10:100335. Published 2022 Mar 15. doi:10.1016/j.ajpc.2022.100335.
Baumer Y, Ng Q, Sanda GE, et al. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. JCI Insight. 2018;3(1):e97179. Published 2018 Jan 11. doi:10.1172/jci.insight.97179.
Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650-656.e3. doi:10.1016/j.jaad.2017.06.028.
Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187-195. doi:10.1177/1759720X15591801.
Karbach S, Croxford AL, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2658-2668. doi:10.1161/ATVBAHA.114.304108.
Mendis S, Pruska P, Norrving B. Global Atlas on Cardiovascular Disease Prevention and Control. In: (Organization WHO, ed). 2011.
Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159 Suppl 2:10-17. doi:10.1111/j.1365-2133.2008.08780.x.
Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366(9491):1059-1062. doi:10.1016/S0140-6736(05)67402-8.
Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57-70. doi:10.1016/j.trsl.2017.01.001.
Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni's 'De sedibus et causis morborum per anatomen indagata'. Int J Obes Relat Metab Disord. 2003;27(4):534-535. doi:10.1038/sj.ijo.0802268.
Stefanadi EC, Dimitrakakis G, Antoniou CK, et al. Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients. Diabetol Metab Syndr. 2018;10:9. Published 2018 Feb 21. doi:10.1186/s13098-018-0311-z.
van Waateringe RP, Slagter SN, van Beek AP, et al. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Diabetol Metab Syndr. 2017;9:42. Published 2017 May 30. doi:10.1186/s13098-017-0241-1.
Padhi T, Garima. Metabolic syndrome and skin: psoriasis and beyond. Indian J Dermatol. 2013;58(4):299-305. doi:10.4103/0019-5154.113950.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Anna Gorajek, Karolina Mkut, Dominik Maj, Małgorzata Witeska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 444
Number of citations: 0
